WCNF
22.9.2021 01:03:09 CEST | Business Wire | Press release
The "World Carbon Neutrality Forum" (WCNF) was announced today by the former President of the European Council (2004) and former Irish Prime Minister Bertie Ahern. Mr Ahern is currently co-chair of the Interaction of Council of Former Heads of State and Government, and the Eco Global Forum.
The date of 22nd September has been chosen to mark the first anniversary of President Xi’s double carbon commitment and his efforts towards a community with a shared future. The Forum is established to promote climate cooperation between China, the United States, Europe, and the rest of the World.
In its first year of operation, the World Carbon Neutrality Forum will be held virtually and transmitted by a dedicated video platform called the World Carbon Neutrality Media Network. The Forum will be based on a Davos model and will seek to stimulate thoughts globally by leadership on decarbonisation. It is a pluralistic organisation which will meet each quarter and will invite current and former Heads of State and Prime Ministers from developed and developing countries to discuss global decarbonisation targets.
The World Carbon Neutrality Forum will be based on the consensus model as proposed in the Paris Climate Agreement - it will bring together government leaders, global companies, institutions, scientists to promote and discuss knowledge of related topics such as climate change, carbon neutrality and new energy technology.
It is committed to empowering the global carbon neutral revolution and promoting the national awakening of green awareness. The Forum has commenced cooperation with several of the world’s leading academic, business, non-governmental organisations and institutions to initiate the first forum which will take place in January 2022.
The “World Carbon Neutrality Media Network" (WCNMN) was announced to commence broadcasting in 2022. It will be a global media and cloud video conference platform similar to TED, which focuses on the national decarbonisation targets and promotes climate cooperation between Europe, China, the United States and the rest of the World. Its objective is to provide a dedicated platform to bring together influential thought leaders.
Ms. Yang Lan, a well-known media proprietor and journalist, will serve as the chief host and be responsible for moderating WCNMN sessions and debates. Other sessions may be conducted to respond to topical issues on climate action and climate change that might arise.
Commenting on the announcement today Mr Ahern said:
“Without doubt climate change is the central issue challenging world leaders economically, politically and socially. What is required of a single generation is a scale of change ordinarily phased in over several decades. The politics to deliver that change will require political courage and skill.”
“Throughout my career I have always tried to cultivate the spirit of partnership and consensus. I am delighted to be Chair of the World Carbon Neutrality Forum because I believe collaboration, cooperation and coalition are key to substantial change. When it comes to climate action – we need borderless dialogue .
“The World Carbon Neutrality Media Network will provide an opportunity for industry leaders and Governments to listen to each other and take practical solutions from each other if we are to collectively realise global decarbonisation targets.
“As part of the European Green Deal , the Commission proposed in September 2020 to raise the 2030 greenhouse gas emission reduction target, including emissions and removals, to at least 55% compared to 1990. It looked at the actions required across all sectors, including increased energy efficiency and renewable energy, and started the process of making detailed legislative proposals by July 2021 to implement and achieve the increased ambition. This will enable the EU to move towards a climate-neutral economy and implement its commitments under the Paris Agreement .
“In addition the clear goal of carbon peak by 2030 and carbon neutrality by 2060 was declared on this day last year by President Xi Jinping of China. Recent announcements from China as well as the recently renewed commitment by the United States to the Paris Agreement means that policy and political momentum are moving in the same direction on carbon neutrality.
“The activity amounts to a paradigm shift and I believe there is an opportunity for a leadership voice to emerge to articulate the value of net zero-carbon target. The World Carbon Neutrality Forum will seek to find our collective voice through a network for like minded political and business leaders and will provide a collaborative forum to motivate and share experience.”
View source version on businesswire.com: https://www.businesswire.com/news/home/20210921006121/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
